Executive SummaryResearch collaboration with Canadian biotech firm Allelix Biopharmaceuticals will focus on bone disorders, including osteoporosis, bone cancer and bone fractures. Glaxo Canada is providing a minimum of $ 10 mil. over five years. One of the first projects will be the production via genetic engineering of parathyroid hormone, for use in treating osteoporosis. Allelix is also investigating the cytokine interleukin-6 for inflammation under an agreement with Rhone-Poulenc.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.